Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

PHASE4CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Multiple Sclerosis
Interventions
DRUG

Fingolimod

0.5 mg in capsules for oral administration once daily

DRUG

Interferon beta 1b

250 μg injected s.c. every other day

Trial Locations (26)

16132

Novartis Investigative Site, Genova

20122

Novartis Investigative Site, Milan

20132

Novartis Investigative Site, Milan

21013

Novartis Investigative Site, Gallarate

24128

Novartis Investigative Site, Bergamo

25018

Novartis Investigative Site, Montichiari

27100

Novartis Investigative Site, Pavia

50134

Novartis Investigative Site, Florence

60126

Novartis Investigative Site, Ancona

63755

Novartis Investigative Site, Alzenau in Unterfranken

66100

Novartis Investigative Site, Chieti

70124

Novartis Investigative Site, Bari

80131

Novartis Investigative Site, Napoli

80138

Novartis Investigative Site, Napoli

86077

Novartis Investigative Site, Pozzilli

90015

Novartis Investigative Site, Cefalù

95122

Novartis Investigative Site, Catania

95123

Novartis Investigative Site, Catania

96049

Novartis Investigative Site, Bamberg

97080

Novartis Investigative Site, Würzburg

98121

Novartis Investigative Site, Messina

04103

Novartis Investigative Site, Leipzig

00133

Novartis Investigative Site, Roma

00161

Novartis Investigative Site, Roma

00179

Novartis Investigative Site, Roma

00189

Novartis Investigative Site, Roma

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY